文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高强度聚焦超声后复发前列腺癌的VMAT挽救放疗:法国大样本回顾性系列及文献综述

Salvage radiotherapy with volumetric modulated arc therapy (VMAT) for recurrent prostate cancer after high-intensity focused ultrasound (HIFU): A large French retrospective series and literature review.
PubMed 文献 · Radiother Oncol · 2024-12-15

该法国多中心回顾性系列纳入2014至2023年间3个放疗中心收治的56例高强度聚焦超声(HIFU)后局部或局部区域复发的前列腺癌患者,评估容积旋转调强放疗(VMAT)挽救放疗的急性和晚期毒性及肿瘤学结局。中位随访19.5个月(12-47)期间无患者出现生化、局部或远处复发,无3级及以上毒性,但作者指出需要更长随访评估疗效。

要点

  • 56例HIFU后复发患者接受VMAT挽救放疗,中位随访19.5个月无生化、局部或远处复发。
  • 急性2级泌尿生殖毒性18例(32%)、胃肠道毒性4例(7%),晚期2级泌尿生殖毒性2例、胃肠道毒性1例,无3级及以上毒性。
  • 作者认为急性毒性可接受、晚期不良事件少,但需要更长随访评估疗效。

核心结论

  • 这是目前最大的采用VMAT及递增剂量(78-80 Gy/39-40次,或60 Gy/20次)进行HIFU后挽救放疗的系列。
  • 急性毒性可接受,晚期不良事件少。
  • 需要更长随访评估疗效。
  • 总体而言,现有系列提示挽救放疗可能是HIFU后复发治疗中有价值的选择。

研究设计与样本

  • 法国3个放疗中心2014至2023年收治的HIFU后局部或局部区域复发并以VMAT行挽救放疗的患者回顾性系列,共56例。
  • 中位复发年龄75岁(70-80),HIFU至挽救放疗中位时间26.5个月(13.9-47.2)。
  • 挽救放疗仅前列腺35例(62.5%),前列腺及盆腔21例(37.5%);常规分割46例(82.1%),大分割10例(17.9%)。
  • 27例(48.2%)接受雄激素剥夺治疗(ADT)。

主要发现

  • 急性2级泌尿生殖不良事件18例(32%),急性2级胃肠道不良事件4例(7%)。
  • 晚期2级泌尿生殖不良事件2例,晚期2级胃肠道不良事件1例。
  • 未报告3级及以上毒性。
  • 中位随访19.5个月(12-47)期间,无患者出现生化、局部或远处复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更长随访评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Although not validated as a standard treatment, high-intensity focused ultrasound (HIFU) is increasingly used in the management of localised prostate cancer (PCa). In case of recurrence after HIFU, treatment is currently not standardised. Our aim was to evaluate normofractionated (NFRT) and hypofractionated (HFRT) salvage radiotherapy (RT) using volumetric modulated arc therapy (s-VMAT) with doses used in first-line management of localised PCa. MATERIAL AND METHODS: We identified all patients with local or locoregional recurrence after HIFU treated with s-VMAT in 3 RT centres between 2014 and 2023. We evaluated acute and late toxicity and oncological outcomes. RESULTS: Fifty-six patients were identified. Median age at recurrence was 75 (70-80) years. Median time between HIFU and s-VMAT was 26.5 months (13.9-47.2). S-VMAT was delivered to the prostate only in 35 (62.5 %) patients and to the prostate and pelvis in 21 (37.5 %) patients. NFRT and HFRT were delivered in 46 (82.1 %) and 10 (17.9 %) patients, respectively. Androgen deprivation therapy (ADT) was given to 27 (48.2 %) patients. Eighteen (32 %) and four (7 %) patients reported an acute grade 2 genitourinary (GU) and gastrointestinal (GI) adverse event (AE), respectively. Two patients presented with a late grade 2 GU AE, and one with a late grade 2 GI AE. No grade 3+ toxicity was reported. With a median follow-up of 19.5 months (12 - 47), no patient had a biochemical, local or distant relapse. CONCLUSIONS: This is the largest series of salvage RT after HIFU using VMAT and escalated doses (78-80 Gy/39-40Fr., or 60 Gy/20Fr.). Acute toxicity was acceptable and late AEs were few. Longer follow-up is required to assess efficacy. Overall, available series suggest that salvage RT could represent a valuable option in the treatment of relapses after HIFU.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Baude J, Teyssier C, Barbier V, et al. Salvage radiotherapy with volumetric modulated arc therapy (VMAT) for recurrent prostate cancer after high-intensity focused ultrasound (HIFU): A large French retrospective series and literature review. Radiother Oncol. 2024. PMID: 39681174. doi:10.1016/j.radonc.2024.110665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。